Haringman Jasper J, Oostendorp Roos L, Tak Paul P
Division of Clinical Immunology and Rheumatology F4-218, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, NL-1105 AZ, Amsterdam, The Netherlands.
Expert Opin Emerg Drugs. 2005 May;10(2):299-310. doi: 10.1517/14728214.10.2.299.
The development of specific targeted therapies, such as anti-TNF-alpha treatment, for chronic inflammatory disorders such as rheumatoid arthritis, has significantly improved treatment, although not all patients respond. Targeting cellular adhesion molecules and chemokines/chemokine receptors as regulators of the extravasation and migration of leukocytes may provide a novel approach for the treatment of these diseases. Moreover, the possibility of developing small-molecule antagonists offers an excellent method for the oral delivery of compounds with a short half-life.
针对类风湿关节炎等慢性炎症性疾病的特异性靶向治疗方法（如抗TNF-α治疗）的发展显著改善了治疗效果，尽管并非所有患者都有反应。将细胞粘附分子和趋化因子/趋化因子受体作为白细胞外渗和迁移的调节因子进行靶向治疗，可能为这些疾病的治疗提供一种新方法。此外，开发小分子拮抗剂的可能性为口服半衰期短的化合物提供了一种很好的方法。
